{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006821","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.081769+00:00","generated_at":"2026-05-15T21:58:06.694055+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint","bullets":["Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.","UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.","Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.","UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.","Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006821","json":"https://secwatch.observer/filing/0001437749-26-006821.json","markdown":"https://secwatch.observer/filing/0001437749-26-006821.md","text":"https://secwatch.observer/filing/0001437749-26-006821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/0001437749-26-006821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/azta20260303_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:58:06.694055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09c96582babc14ce62d36d0c07f231c073bca4e8","claim":"Azenta, Inc. entered into Share Purchase Agreement with UK Biocentre Limited valued at GBP 20.5 million (effective 2026-03-04).","evidence_excerpt":"On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Share Purchase Agreement (“Agreement”) under which Azenta UK Ltd. acquired all the issued and outstanding share capital of UK Biocentre Limited (“UK Biocentre”), a provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/0001437749-26-006821-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"UK Biocentre Limited"},{"label":"Value","value":"GBP 20.5 million"},{"label":"Effective","value":"2026-03-04"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}